LINCOLN636.70

Lincoln Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersSIGACHITHEMISMEDBAJAJHCAREAMRUTANJANJAGSNPHARMWANBURYAHCLMcap ₹1,275 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
LINCOLN
FY26
SIGACHI
FY26
THEMISMED
FY26
BAJAJHCARE
FY26
Peer
Median
Valuation — at last close
P/E14.51×1100.00×66.57×583.28× -98%
P/B1.68×2.72×3.05×2.09×2.72× -38%
EV/EBITDA10.75×28.86×3334.88×12.52×28.86× -63%
Market Cap₹1,275 Cr₹1,437 Cr₹1,216 Cr₹1,116 Cr₹1,216 Cr +5%
Growth
Revenue CAGR 3Y9.56%16.52%-1.15%-3.18%-1.15% +931%
Revenue CAGR 5Y8.21%8.21%
Net Income CAGR 3Y6.43%-72.81%-28.44%-50.63% +113%
Revenue YoY (latest Q)15.07%-5.44%-10.88%11.28%-5.44% +377%
Net Income YoY (latest Q)30.93%108.07%273.08%15.75%108.07% -71%
Profitability
EBITDA Margin14.56%11.25%0.11%17.15%11.25% +29%
Net Income Margin13.10%-17.33%0.33%2.58%0.33% +3870%
Return on Common Equity11.60%-15.46%0.29%2.96%0.29% +3900%
Return on Capital Employed10.67%6.34%-2.30%12.80%6.34% +68%
Return on Assets9.87%-9.84%0.19%1.71%0.19% +5095%
Credit & Quality
Total Debt/Equity0.01×0.26×0.25×0.44×0.26× -96%
Interest Coverage82.12×2.60×-0.93×3.48×2.60× +3058%
Scale — latest FY
Revenue / Total Income₹671 Cr₹478 Cr₹342 Cr₹611 Cr₹478 Cr +40%
Net Income₹87.9 Cr−₹82.8 Cr₹1.1 Cr₹15.8 Cr₹1.1 Cr +7585%
Total Assets₹890 Cr₹841 Cr₹598 Cr₹923 Cr₹841 Cr +6%
EPS₹43.88₹-2.14₹0.12₹4.98₹0.12 +36467%
Book Value per Share₹378.25₹13.84₹43.28₹158.34₹43.28 +774%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.